Shanghai MicroPort EP MedTech Co ("MicroPort® EP") recently attended the 13th China Atrial Fibrillation Symposium ("CAFS") held from July 9 to July 12 in Dalian, to promote our Columbus™ 3D EP Navigation System ("Columbus™").
On July 11, MicroPort® EP hosted a satellite meeting titled Columbus™ Clinical Project Report, which attracted more than 100 attendees. The meeting was co-chaired by Professor Yanzong Yang and Professor Lianjun Gao from the First Affiliated Hospital of Dalian Medical University, Professor Yansheng Ding from Peking University First Hospital, and Professor Zulu Wang from the General Hospital of Shenyang Military.
During the satellite meeting, Professor Jianzeng Dong of Capital Medical University Affiliated Beijing Anzhen Hospital explained the clinical trial results of Columbus™ and noted that its one-year follow-up success rate of curing persistent atrial fibrillation with single ablation stood at 67.1%, which was better than the 22.8% success rate of anti-arrhythmic drugs and has reached world-class level. Professor Pingzhen Yang from Zhujiang Hospital of Southern Medical University introduced Columbus™ in general and presented its advantages, such as stable performance during procedure, real-time observation and analysis of electrical signal change in the process of atrial fibrillation ablation, and incorporating multi-channel EP recording functions. Professor Zhibing Lu from Renmin Hospital of Wuhan University and Professor Ming Liang from the General Hospital of Shenyang Military also shared their experience in using Columbus™. Many experts spoke highly of Columbus™ and expected its market launch in China.
Aside from Columbus™, MicroPort® EP also displayed some other new products including PathBuilder™ Transseptal Introducer and Needle and Steerable Bi-directional Introducer in its booth, which attracted a lot of attention from experts in attendance.